|
1
|
Woolf SH: Screening for prostate cancer
with prostate-specific antigen. An examination of the evidence. N
Engl J Med. 333:1401–1405. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Oh WK and Kantoff PW: Management of
hormone refractory prostate cancer: Current standards and future
prospects. J Urol. 160:1220–1229. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li TH, Zhao H, Peng Y, Beliakoff J, Brooks
JD and Sun Z: A promoting role of androgen receptor in
androgen-sensitive and -insensitive prostate cancer cells. Nucleic
Acids Res. 35:2767–2776. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Huggins C: Endocrine-induced regression of
cancers. Cancer Res. 27:1925–1930. 1967.PubMed/NCBI
|
|
5
|
Debes JD and Tindall DJ: Mechanisms of
androgen-refractory prostate cancer. N Engl J Med. 351:1488–1490.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nguyen MM and Wang Z: Manipulation of
androgens and alterations in the androgen receptor axis in prostate
cancer. Minerva Urol Nefrol. 60:15–29. 2008.PubMed/NCBI
|
|
8
|
Grossmann ME, Huang H and Tindall DJ:
Androgen receptor signaling in androgen-refractory prostate cancer.
J Natl Cancer Inst. 93:1687–1697. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Craft N, Shostak Y, Carey M and Sawyers
CL: A mechanism for hormone-independent prostate cancer through
modulation of androgen receptor signaling by the HER-2/neu tyrosine
kinase. Nat Med. 5:280–285. 1999. View
Article : Google Scholar
|
|
10
|
Linja MJ and Visakorpi T: Alterations of
androgen receptor in prostate cancer. J Steroid Biochem Mol Biol.
92:255–264. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Vis AN and Schröder FH: Key targets of
hormonal treatment of prostate cancer. Part 1: the androgen
receptor and steroidogenic pathways. BJU Int. 104:438–448. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Culig Z, Hobisch A, Cronauer MV, et al:
Androgen receptor activation in prostatic tumor cell lines by
insulin-like growth factor-I, keratinocyte growth factor and
epidermal growth factor. Eur Urol. 27(Suppl 2): 45–47. 1995.
|
|
13
|
Dorsam RT and Gutkind JS:
G-protein-coupled receptors and cancer. Nat Rev Cancer. 7:79–94.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Daaka Y: G proteins in cancer: The
prostate cancer paradigm. Sci STKE: re2. 2004.PubMed/NCBI
|
|
15
|
Mendiratta P, Armstrong AJ and George DJ:
Current standard and investigational approaches to the management
of hormone-refractory prostate cancer. Rev Urol. 9:S9–S19.
2007.PubMed/NCBI
|
|
16
|
Raj GV, Barki-Harrington L, Kue PF and
Daaka Y: Guanosine phosphate binding protein coupled receptors in
prostate cancer: A review. J Urol. 167:1458–1463. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Xia C, Ma W, Wang F, Hua SB and Liu M:
Identification of a prostate-specific G-protein coupled receptor in
prostate cancer. Oncogene. 13:5903–5907. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang J, Weng J, Cai Y, Penland R, Liu M
and Ittmann M: The prostate-specific G-protein coupled receptors
PSGR and PSGR2 are prostate cancer biomarkers that are
complementary to alpha-methylacyl-CoA racemase. Prostate.
1:847–857. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weng J, Wang J, Cai Y, et al: Increased
expression of prostate-specific G-protein-coupled receptor in human
prostate intraepithelial neoplasia and prostate cancers. Int J
Cancer. 113:811–818. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yowell CW and Daaka Y: G protein-coupled
receptors provide survival signals in prostate cancer. Clin
Prostate Cancer. 1:177–181. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sun L, Luo J, Mackey LV, et al:
Investigation of cancer cell lines for peptide receptor-targeted
drug development. J Drug Target. 19:719–730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gutkind JS: Regulation of
mitogen-activated protein kinase signaling networks by G
protein-coupled receptors. Sci STKE: re1. 2000.PubMed/NCBI
|
|
23
|
McDonnell TJ, Troncoso P, Brisbay SM, et
al: Expression of the Protooncogene bcl-2 in the Prostate and Its
Association with Emergence of Androgen-independent Prostate Cancer.
Cancer Res. 52:6940–6944. 1992.PubMed/NCBI
|
|
24
|
Kasbohm EA, Guo R, Yowell CW, et al:
Androgen receptor activation by G (s) signaling in prostate cancer
cells. J Biol Chem. 280:11583–11589. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Merkle D and Hoffmann R: Roles of cAMP and
cAMP-dependent protein kinase in the progression of prostate
cancer: Cross-talk with the androgen receptor. Cell Signal.
23:507–515. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luscombe CJ, French ME, Liu S, et al:
Prostate cancer risk: Associations with ultraviolet radiation,
tyrosinase and melanocortin-1 receptor genotypes. Br J Cancer.
85:1504–1509. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wisse BE, Frayo RS, Schwartz MW and
Cummings DE: Reversal of cancer anorexia by blockade of central
melanocortin receptors in rats. Endocrinology. 142:3292–3301. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen W, Kelly MA, Opitz-Araya X, Thomas
RE, Low MJ and Cone RD: Exocrine gland dysfunction in
MC5-R-deficient mice: Evidence for coordinated regulation of
exocrine gland function by melanocortin peptides. Cell. 91:789–798.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Roy S, Pinard S, Chouinard L and
Gallo-Payet N: Adreno-corticotropin hormone (ACTH) effects on MAPK
phosphorylation in human fasciculata cells and in embryonic kidney
293 cells expressing human melanocortin 2 receptor (MC2R) and MC2R
accessory protein (MRAP)β. Mol Cell Endocrinol. 336:31–40.
2011.
|
|
30
|
Alwani RA, Neggers SJ, van der Klift M, et
al: Cushing’s syndrome due to ectopic ACTH production by
(neuroendocrine) prostate carcinoma. Pituitary. 12:280–283.
2009.
|
|
31
|
Mansour M, Schwartz D, Judd R, et al:
Thiazolidinediones/PPARγ agonists and fatty acid synthase
inhibitors as an experimental combination therapy for prostate
cancer. Int J Oncol. 38:537–546. 2011.
|
|
32
|
Tao YX, Huang H, Wang ZQ, Yang F, Williams
JN and Nikiforovich GV: Constitutive activity of neural
melanocortin receptors. Methods Enzymol. 484:267–279. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mansour M, White D, Wernette C, et al:
Pancreatic neuronal melanocortin-4 receptor modulates serum insulin
levels independent of leptin receptor. Endocrine. 37:220–230. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Marinissen MJ and Gutkind JS:
G-protein-coupled receptors and signaling networks: emerging
paradigms. Trends Pharmacol Sci. 22:368–376. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Labrie F, Belanger A, Dupont A, Luu-The V,
Simard J and Labrie C: Science behind total androgen blockade: from
gene to combination therapy. Clin Invest Med. 16:475–492.
1993.PubMed/NCBI
|
|
36
|
Roy S, Rached M and Gallo-Payet N:
Differential regulation of the human adrenocorticotropin receptor
[melanocortin-2 receptor (MC2R)] by human MC2R accessory protein
isoforms alpha and beta in isogenic human embryonic kidney 293
cells. Mol Endocrinol. 21:1656–1669. 2007.
|
|
37
|
Cone RD: Studies on the physiological
functions of the melanocortin system. Endocr Rev. 27:736–749. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Abdel-Malek Z, Swope VB, Suzuki I, et al:
Mitogenic and melanogenic stimulation of normal human melanocytes
by melanotropic peptides. Proc Natl Acad Sci USA. 92:1789–1793.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Melmed S: Pathogenesis of pituitary
tumors. Nat Rev Endocrinol. 7:257–266. 2011. View Article : Google Scholar
|
|
40
|
Liddle GW, Island DP, Ney RL, Nicholson WE
and Shimizu N: Nonpituitary neoplasms and cushing’s syndrome:
Ectopic ‘adrenocorticotropin’ produced by nonpituitary neoplasms as
a cause of Cushing’s syndrome. Arch Intern Med. 111:471–475.
1963.
|
|
41
|
Gewirtz G and Yalow RS: Ectopic ACTH
production in carcinoma of the lung. J Clin Invest. 53:1022–1032.
1974. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Singer W, Kovacs K, Ryan N and Horvath E:
Ectopic ACTH syndrome: clinicopathological correlations. J Clin
Pathol. 31:591–598. 1978. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Halkerston ID: Cyclic AMP and
adrenocortical function. Adv Cyclic Nucleotide Res. 6:99–136.
1975.PubMed/NCBI
|
